Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods

• US 5,532,225 A
• Filed: 07/31/1992
• Issued: 07/02/1996
• Est. Priority Date: 07/31/1992
• Status: Expired due to Fees

• Current Assignee: SRI International, Inc.
• Original Assignee: SRI International, Inc.
• Inventors: Reist, Elmer J., Ruhland-Fritsch, Beatrice, Sturm, Pricilla A.
• Primary Examiner(s): BERNHARDT, EMILY A
• Application Number:
  US07/922,937
• Time in Patent Office: 1,432 Days
• Field of Search: 544/244, 514/81
• US Class Current: 514/81
• CPC Class Codes: C07F 9/65616 containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
• CPC Class Codes: C07F 9/657181 the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Abstract

Acyclic purine phosphonate nucleotide analogs useful to treat herpes viral infections are provided in enantiomerically pure form. These antiviral agents have the structural formula (Ia) or (Ib) ##STR1## and may be in acid, salt or ester form. Such compounds may also be dehydrated to provide antiviral agents in cyclic form. Pharmaceutical compositions are provided containing the antiviral agents, as is a chiral synthesis which may be used to prepare the agents in enantiomerically pure form or as a racemic mixture.

Claims

1. A compound having the structural formula (VIIIb) ##STR17## in enantiomerically pure form.

2. A pharmaceutical composition for treating herpes viral infection which comprises an effective amount of the compound of claim 1 in admixture with a pharmaceutically acceptable excipient.

3. A method to treat herpes viral infection in an infected subject, which comprises administering to the subject an effective amount of the compound of claim 1 in admixture with a pharmaceutically acceptable excipient.